Charles River Laboratories stock slips 2.23% and underperforms peers

6 articles · Updated · MarketWatch · May 8

Shares closed at $177.62 on Friday, their third straight daily loss, as the S&P 500 rose 0.84% and the Dow Jones Industrial Average edged up 0.02%.
The stock finished 22.40% below its 52-week high of $228.88 reached on 13 January, lagging a generally favourable broader market session.
Among peers, Labcorp fell 1.52%, Alnylam Pharmaceuticals slipped 0.29%, and Bio-Techne dropped 5.01%, leaving Charles River's performance mixed relative to competitors.

With animal testing declining, can Charles River's pivot to new tech outpace its shrinking legacy business?

As Charles River sells off major assets, why is its own financial forecast for the year getting worse?